Literature DB >> 23301543

Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation.

J R Larrubia1, M U Lokhande, S García-Garzón, J Miquel, A González-Praetorius, T Parra-Cid, E Sanz-de-Villalobos.   

Abstract

In persistent hepatitis C virus (HCV) infection, HCV-specific cytotoxic T lymphocyte (CTL) reactivity is impaired and this affects HCV control. Interleukin-7 receptor (CD127) expression on these cells could regulate CTL reactivity through Mcl-1/Bim balance modulation. Bim is a pro-apoptotic molecule blocked by the action of Mcl-1. Mcl-1/Bim expression and T cell reactivity on HCV-specific CTLs were compared according to CD127 phenotype. Peripheral blood lymphocytes (PBL) from HLA-A2(+) HCV(+) patients were obtained. HCV-specific CTLs were visualized by staining PBL with anti-CD8 and HLA-A2/peptide pentameric complexes (pentamer). Mcl-1/Bim/CD127 phenotype of HCV-specific CTLs was tested by staining detectable CD8(+)/pentamer(+) cells with anti-Mcl-1/Bim/CD127 antibodies. HCV-specific CTL proliferation ability after specific in vitro challenge was tested in the presence and absence of pancaspase inhibitor z-VAD-fmk. All stained cells were analysed by flow cytometry. CD127(low)-expressing HCV-specific CTLs associated with high HCV viraemia, while CD127(high) correlated with undetectable viral loads (P < 0.001). Directly ex vivo, pentamer(+) cell frequency was similar according to CD127 expression level. Nevertheless, CD127(low) pentamer(+) cell proliferation after specific in vitro challenge was impaired (P < 0.05), although this was corrected by z-VAD-fmk treatment (P < 0.05). Mcl-1 expression was low directly ex vivo (P < 0.01), and Bim was up-regulated after antigen encounter (P < 0.05) of CD127(low) pentamer(+) cells. The ex vivo difference between Mcl-1 and Bim expression on pentamer(+) cells correlated positively with CD127 expression level (P < 0.001) and with pentamer(+) cell reactivity (P < 0.05). In summary, a low ex vivo Mcl-1 expression and Bim up-regulation after antigen encounter are involved in CD127(low) HCV-specific CTL hyporeactivity during chronic infection, but it can be overcome by apoptosis blockade.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23301543     DOI: 10.1111/j.1365-2893.2012.01618.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Authors:  Chelsey J Judge; Lenche Kostadinova; Kenneth E Sherman; Adeel A Butt; Yngve Falck-Ytter; Nicholas T Funderburg; Alan L Landay; Michael M Lederman; Scott F Sieg; Johan K Sandberg; Donald D Anthony
Journal:  J Leukoc Biol       Date:  2017-04-11       Impact factor: 4.962

Review 3.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 4.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 5.  Hepatitis viruses exploitation of host DNA methyltransferases functions.

Authors:  Valerio Pazienza; Concetta Panebianco; Angelo Andriulli
Journal:  Clin Exp Med       Date:  2015-07-07       Impact factor: 3.984

6.  Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.

Authors:  M Guzmán-Fulgencio; J Berenguer; D Pineda-Tenor; M A Jiménez-Sousa; M García-Álvarez; T Aldámiz-Echevarria; A Carrero; C Diez; F Tejerina; S Vázquez; V Briz; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-19       Impact factor: 3.267

7.  According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.

Authors:  Elia Moreno-Cubero; Dolores Subirá; Eduardo Sanz-de-Villalobos; Trinidad Parra-Cid; Antonio Madejón; Joaquín Miquel; Antonio Olveira; Alejandro González-Praetorius; Javier García-Samaniego; Juan-Ramón Larrubia
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 8.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Authors:  Elia Moreno-Cubero; Juan-Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 10.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.